Pharmacoepidemiology, Fourth Edition

Pharmacoepidemiology, Fourth Edition

Editor(s): Brian L. Strom

Published Online: 14 MAR 2007

Print ISBN: 9780470866818

Online ISBN: 9780470059876

DOI: 10.1002/9780470059876

About this Book

The fourth edition of Pharmacoepidemiology is an outstanding and fully comprehensive textbook, which will be an essential resource for all interested in the field-in academia, in regulatory agencies, in industry and in the law.  Brian Strom's classic textbook continues both to reflect the increased maturation of pharmacoepedemiology and to help shape it's direction.

 Reviews of previous editions of his celebrated textbook include:

"The book is essential reading for anyone interested in pharmacoepidemiology."

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

"…an excellent textbook and a comprehensive reference which belongs inthe library of every pharmaceutical manufacturer and regulator."

EUROPEAN JOURNAL OF PUBLIC HEALTH 

Table of contents

    1. You have free access to this content
  1. Part I: Introduction

  2. Part II: Perspectives on Pharmacoepidemiology

    1. Chapter 7

      A View from Industry (pages 77–101)

      Robert F. Reynolds, Dale B. Glasser and Gretchen S. Dieck

    2. Chapter 8

      A View from Regulatory Agencies (pages 103–130)

      Peter Arlett, Jane Moseley and Paul J. Seligman

  3. Part III: Sources of Data for Pharmacoepidemiology Studies: Ad Hoc Data Sources Available for Pharmacoepidemiology Studies

    1. Chapter 9

      Spontaneous Reporting in the United States (pages 131–159)

      Syed Rizwanuddin Ahmad, Roger A. Goetsch and Norman S. Marks

    2. Chapter 11

      Case–Control Surveillance (pages 185–202)

      Lynn Rosenberg, Patricia F. Coogan and Julie R. Palmer

  4. Part III: Sources of Data for Pharmacoepidemiology Studies: Automated Data Systems Available for Pharmacoepidemiology Studies

    1. Chapter 14

      Group Health Cooperative (pages 223–239)

      Kathleen W. Saunders, Robert L. Davis and Andy Stergachis

    2. Chapter 15

      Kaiser Permanente Medical Care Program (pages 241–259)

      Joe V. Selby, David H. Smith, Eric S. Johnson, Marsha A. Raebel, Gary D. Friedman and Bentson H. McFarland

    3. Chapter 16

      The HMO Research Network (pages 261–269)

      K. Arnold Chan, Robert L. Davis, Margaret J. Gunter, Jerry H. Gurwitz, Lisa J. Herrinton, Winnie W. Nelson, Marsha A. Raebel, Douglas W. Roblin, David H. Smith and Richard Platt

    4. Chapter 17

      UnitedHealth Group (pages 271–280)

      Deborah Shatin, Nigel S. B. Rawson and Andy Stergachis

    5. Chapter 18

      Medicaid Databases (pages 281–294)

      Sean Hennessy, Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom

    6. Chapter 19

      Health Services Databases in Saskatchewan (pages 295–310)

      Winanne Downey, Maryrose Stang, Patricia Beck, William Osei and James L. Nichol

  5. Part III: Sources of Data for Pharmacoepidemiology Studies: Other Approaches to Pharmacoepidemiology Studies

  6. Part IV: Selected Special Applications of Pharmacoepidemiology

    1. Chapter 28

      Evaluating and Improving Physician Prescribing (pages 419–437)

      Sumit R. Majumdar, Helene Levens Lipton and Stephen B. Soumerai

    2. Chapter 29

      Drug Utilization Review (pages 439–453)

      Sean Hennessy, Stephen B. Soumerai, Helene Levens Lipton and Brian L. Strom

    3. Chapter 33

      Pharmacoepidemiology and Risk Management (pages 515–530)

      David J. Graham, Andrew D. Mosholder, Kate Gelperin and Mark I. Avigan

  7. Part V: Selected Special Methodologic Issues in Pharmacoepidemiology

    1. Chapter 37

      Molecular Pharmacoepidemiology (pages 571–586)

      Stephen E. Kimmel, Hubert G. Leufkens and Timothy R. Rebbeck

    2. Chapter 38

      Bioethical Issues in Pharmacoepidemiologic Research (pages 587–598)

      David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan

    3. Chapter 47

      Bias and Confounding in Pharmacoepidemiology (pages 791–809)

      Ilona Csizmadi, Jean-Paul Collet and Jean-François Boivin

  8. Part VI: Conclusion

    1. You have free access to this content
    1. You have free access to this content
    1. You have free access to this content

SEARCH